Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Reem Karmali, Kevin A. David et al.|Journal of Hematology & Oncology|2023Cited by 52
Decreasing chronic graft-versus-host disease rates in all populationsPaul A. Carpenter, Stephanie J. Lee, Julie R. Boiko et al.|Blood Advances|2024Cited by 23
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistryMaría Silvina Odstrcil Bobillo, Matthew J. Frigault, Swetha Kambhampati et al.|Blood|2024Cited by 7
Assessing Quality of Life and Symptoms in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCTRahul Banerjee, Betty K. Hamilton, Hermioni L. Amonoo et al.|Transplantation and Cellular Therapy|2025Cited by 7
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomaJennifer L. Crombie, Iris Isufi, Sairah Ahmed et al.|Blood|2026Cited by 1